KV Pharmaceutical e-mail alert overstated drug efficacy

The FDA says a KV Pharmaceutical e-mail alert announcing the availability of Clindesse on a formulary overstated and misrepresented the efficacy of the drug, which is indicated for treating bacterial vaginosis. The FDA says the e-mail presents unsubstantiated superiority and patient compliance claims, and minimizes the risks and limitations.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions